Hematopoietic growth factors, such as erythropoietin (EPO) and interleukin- 3 (IL-3) activate specific cytokine receptors on the surface of immature blood cells, thereby leading to cellular proliferation and differentiation. Defects in cytokine receptor signaling can lead to ineffective hematopoiesis deficiency; constitutive activation of receptor signaling can lead to overproliferation and leukemogenesis. One pathway activated by cytokine receptors, the JAK/STAT pathway, accounts at least in part for the specificity of the signal transmitted by each cytokine. Using an interactive strategy of mammalian cell culture, transgenic mouse technology, and Drosophila genetics, we plan to study various aspects of the JAK/STAT pathway.
In Specific Aim #1, having identified a point mutation (a hyperactive mutation) in a Drosophila JAK kinase that causes """"""""fly leukemia"""""""", we will explore the effects of overexpressing a hyperactive jAK2 kinase cells or transgenic mice.
In Specific Aim #2, having identified a mutant form of a Drosophila STAT protein that suppresses """"""""fly leukemia"""""""", we will construct and assay dominant inhibitory forms of mammalian STAT proteins.
In Specific Aims #3 and #4 we will explore the interaction of the JAK/STAT path signaling pathway with other signaling pathways, such as the Ras/Raf/MAP kinase pathway. Finally, in Specific Aim #5, we will characterize a novel signaling pathway that is specifically activated by the betac subunit of the IL-3 Receptor and evaluate its relationship to the JAK/STAT pathway.

Project Start
1998-09-25
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Jiang, Jingrui; Griffin, James D (2010) Wnt/?-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3? Dependent Manner. Genes Cancer 1:164-76
Weisberg, E; Ray, A; Barrett, R et al. (2010) Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 24:2100-9
Weisberg, Ellen; Roesel, Johannes; Furet, Pascal et al. (2010) Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer 1:1021-32
Weisberg, Ellen; Choi, Hwan Geun; Ray, Arghya et al. (2010) Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 115:4206-16
Weisberg, E; Deng, X; Choi, H G et al. (2010) Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia 24:1375-8
Weisberg, Ellen; Choi, Hwan Geun; Barrett, Rosemary et al. (2010) Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther 9:2468-77
Moldovan, George-Lucian; Madhavan, Mahesh V; Mirchandani, Kanchan D et al. (2010) DNA polymerase POLN participates in cross-link repair and homologous recombination. Mol Cell Biol 30:1088-96
Weisberg, E; Sattler, M; Ray, A et al. (2010) Drug resistance in mutant FLT3-positive AML. Oncogene 29:5120-34
Kim, Jung Min; Parmar, Kalindi; Huang, Min et al. (2009) Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell 16:314-20
Mercher, Thomas; Raffel, Glen D; Moore, Sandra A et al. (2009) The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest 119:852-64

Showing the most recent 10 out of 111 publications